Allena Pharmaceuticals Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Allena Pharmaceuticals stock.
View analyst ratings for Allena Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Allena Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allena Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Allena Pharmaceuticals.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) issued its quarterly earnings data on Monday, May, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01.
View Allena Pharmaceuticals' earnings history.

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALNA stock has increased by 0.8% and is now trading at $1.27.
View which stocks have been most impacted by COVID-19.

5 analysts have issued 1-year price targets for Allena Pharmaceuticals' shares. Their forecasts range from $5.00 to $18.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 726.8% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Allena Pharmaceuticals include Innate Pharma (IPHA), Eiger BioPharmaceuticals (EIGR), INmune Bio (INMB), ADMA Biologics (ADMA), CASI Pharmaceuticals (CASI), Immatics (IMTX), Applied Genetic Technologies (AGTC), Cabaletta Bio (CABA), Genfit (GNFT), X4 Pharmaceuticals (XFOR), Fennec Pharmaceuticals (FENC), Voyager Therapeutics (VYGR), Axcella Health (AXLA), Gamida Cell (GMDA) and Ayala Pharmaceuticals (AYLA).
View all of ALNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Allena Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (5.20%), Worth Venture Partners LLC (1.70%), Morgan Stanley (1.11%), Renaissance Technologies LLC (0.84%), Geode Capital Management LLC (0.44%) and BlackRock Inc. (0.33%). Company insiders that own Allena Pharmaceuticals stock include Edward Wholihan and Louis Md Brenner.
View institutional ownership trends for Allena Pharmaceuticals.

ALNA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, Millennium Management LLC, and Golden Green Inc.. Company insiders that have sold Allena Pharmaceuticals company stock in the last year include Edward Wholihan, and Louis Md Brenner.
View insider buying and selling activity for Allena Pharmaceuticals or view top insider-selling stocks.

ALNA stock was acquired by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC, Renaissance Technologies LLC, Geode Capital Management LLC, Bank of New York Mellon Corp, BlackRock Inc., HRT Financial LP, and Harbor Financial Services LLC.
View insider buying and selling activity for Allena Pharmaceuticals or or view top insider-buying stocks.

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNA stock can currently be purchased for approximately $1.27.

Allena Pharmaceuticals has a market capitalization of $73.27 million. The company earns $-32,850,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

Allena Pharmaceuticals employs 45 workers across the globe.

The official website for Allena Pharmaceuticals is www.allenapharma.com.

Allena Pharmaceuticals is headquartered at ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462.

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577 or via email at [email protected]